MARATTO

article · In Silico Research in Biomedicine

Computational studies on Morpho Butterfly Wings-based compounds as potential Human 3-alpha Hydroxysteroid Dehydrogenase type 3 inhibitors

Abstract

Cancer continues to pose a significant health threat due to the rapid development of drug resistance. To tackle this issue, compounds derived from Morpho Butterfly Wings were assessed for their potential anti-cancer properties using computational methods. Quantum chemical optimization was conducted using density functional theory, and receptor interactions were evaluated through induced-fit docking and molecular dynamics simulations. The findings indicated that 3,8-dimethoxy-2,7-dihydrobenzo[1,2,3-cd:4,5,6-c'd']diindole-4,5,9,10-tetraone (compound 4) exhibited a heightened electron-donating ability due to its narrow HOMO–LUMO gap, while 3,8-dinitro-2,7-dihydrobenzo[1,2,3-cd:4,5,6-c'd']diindole-4,5,9,10-tetraone (compound 6) showed a strong electron-accepting characteristic with its minimal LUMO energy. Additionally, the docking studies identified compound 6 as the leading potential inhibitor, which led to its selection for molecular dynamics simulations; however, the subsequent binding free energy assessments, along with RMSD and RMSF evaluations, demonstrated that it possessed lower dynamic stability and a reduced binding affinity compared to the reference compound, Doxorubicin.

Research topics

  • Synthesis and Characterization of Pyrroles
  • Cholinesterase and Neurodegenerative Diseases
  • Aldose Reductase and Taurine

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1016/j.insi.2026.100268

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.